| Overview |
| bsm-70581M |
| p21/CIP1/WAF1 Antibody |
| WB, IP, IHC |
| The antibody detects a 21 kDa* protein corresponding to the apparent molecular mass of p21 on SDS-PAGE immunoblots of human endothelial cells (HUVEC), HeLa cells, and Fibroblasts. The antibody is also useful for immunoprecipitation and immunofluorescent labeling in human cells. |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| Clone M513 was generated from a full length recombinant human p21 protein. The antibody detects human p21. |
| Monoclonal |
| #REF! |
| IgG2a |
| Antigen Affinity purification |
| PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol |
| Storage at -20C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20C. |
| Target |
| P38936 |
| Cyclin-dependent kinase inhibitor 1
CDK-interacting protein 1
Melanoma differentiation-associated protein 6
MDA-6 p21 CDKN1A CAP20, CDKN1, CIP1, MDA6, PIC1, SDI1, WAF1 |
| The tumor suppressor protein p21/CIP1/WAF1 acts as an inhibitor of cell cycle progression. It functions in stoichiometric relationships forming heterotrimeric complexes with cyclins and cyclin-dependent kinases. In association with CDK2 complexes, it serves to inhibit kinase activity and block progression through G1/S. However, p21 may also enhance assembly and activity in complexes of CDK4 or CDK6 and cyclin D. The carboxy-terminal region of p21 is sufficient to bind and inhibit PCNA, a subunit of DNA polymerase, and may coordinate DNA replication with cell cycle progression. Upon UV damage or during cell cycle stages when cdc2/cyclin B or CDK2/cyclin A are active, p53 is phosphorylated and upregulates p21 transcription via a p53-responsive element. Protein levels of p21 are downregulated through ubiquitination and proteasomal degradation. |
| Application Dilution |
| WB |
1:300-5000 |
| IP |
1-2ug |
| IHC |
|
Powered by Bioz